DAX25.286 -0,5%Est506.005 -0,4%MSCI World4.343 -0,1%Top 10 Crypto12,94 +3,4%Nas23.472 -1,0%Bitcoin83.765 +2,4%Euro1,1642 ±-0,0%Öl64,32 -1,7%Gold4.631 +1,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Bayer BAY001 NVIDIA 918422 TKMS thyssenkrupp Marine Systems TKMS00 Novo Nordisk A3EU6F Deutsche Telekom 555750 BioNTech (ADRs) A2PSR2 RENK RENK73 DroneShield A2DMAA Lufthansa 823212 Siemens Energy ENER6Y Infineon 623100 SAP 716460 Allianz 840400 BASF BASF11
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX beendet Handel im Minus -- Wall Street fällt -- NVIDIA: Exportgenehmigung für China & Milliardendeal mit Eli Lilly -- Gold und Silber, Lufthansa, Krypto, Bayer, Alibaba, Moderna im Fokus
Top News
Attraktive Zinsen ohne Tagesgeld oder Festgeld? Die clevere Alternative für Sparer und Anleger Attraktive Zinsen ohne Tagesgeld oder Festgeld? Die clevere Alternative für Sparer und Anleger
Hot Stocks heute: Aktien in der Besprechung: STRABAG, Exxon Mobile, Chevron - Update: DAX Discount Short  Hot Stocks heute: Aktien in der Besprechung: STRABAG, Exxon Mobile, Chevron - Update: DAX Discount Short 
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Protalix BioTherapeutics Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
1,74 EUR +0,03 EUR +1,75 %
STU
2,06 USD +0,04 USD +1,98 %
BTT
Protalix BioTherapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.144,98 Mio. EUR

KGV51,37Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PWSL

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS74365A3095

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolPLX

Protalix BioTherapeutics Aktien News

DatumMeistgelesen
PR NewswireProtalix BioTherapeutics Letter to Stockholders
PR NewswireProtalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
PR NewswireProtalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
Wer­bungProtalix BioTherapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireProtalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
PR NewswireProtalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
PR NewswireProtalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results
PR NewswireProtalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025
PR NewswireProtalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer
PR NewswireProtalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®
PR NewswireProtalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
PR NewswireProtalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results
PR NewswireProtalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025
PR NewswireProtalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025
PR NewswireProtalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results
PR NewswireProtalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025
PR NewswireProtalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
PR NewswireProtalix BioTherapeutics Issues 2025 Letter to Stockholders
PR NewswireChiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa
PR NewswireProtalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results
PR NewswireProtalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024
PR NewswireProtalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024
PR NewswireProtalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
PR NewswireProtalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes
PR NewswireProtalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results
PR NewswireProtalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024
PR NewswireProtalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout
PR NewswireProtalix BioTherapeutics to Present at the 2024 BIO International Convention
PR NewswireProtalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results
PR NewswireProtalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024
PR NewswireProtalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
PR NewswireProtalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024
PR NewswireProtalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference
PR NewswireProtalix BioTherapeutics Issues 2024 Letter to Stockholders
PR NewswireProtalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results
PR NewswireProtalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023
PR NewswireProtalix BioTherapeutics Issues Statement Regarding Security Situation in Israel
PR NewswireProtalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
PR NewswireProtalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Protalix BioTherapeutics News

Protalix BioTherapeutics News: auf dieser Seite finden Sie alle Protalix BioTherapeutics News und Nachrichten zur Protalix BioTherapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Protalix BioTherapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Protalix BioTherapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.